U.S. government researchers found a widely prescribed asthama drug originally sold by Merck & Co (MRK) may be linked to serious mental health problems, Dan Levine and Sheila Dang of Reuters reports, citing a scientific presentation. The researchers found that the drug, sold under brand name Singulair and generically as montelukast, attaches to multiple brain receptors critical to psychiatric functioning.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRK:
- Pyxis Oncology announces preliminary PYX-201 data, collaboration with Merck
- Target reports downbeat Q3, Comcast plans cable TV spinoff: Morning Buzz
- Johnson & Johnson, Merck cutting jobs in China, Bloomberg reports
- Merck target upped at Jefferies after ‘important win’ with subcutaneous Keytruda
- Merck ‘linked’ to takeover bid for Incyte, Sky News says
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
